Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.2K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.2K
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

904
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
904
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

879
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
879
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

1.4K
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.4K
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

776
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
776
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

635
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
635

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From design to application: chiral Cu based metal-organic frameworks for superior enantioselective resolution.

Journal of chromatography. A·2026
Same author

[Construction of DNA vaccine pcDNA3.1(+)/tetraspanin 2-A against Schistosoma japonicum and its immune-protective effect in mice].

Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases·2010
Same author

Fluorescence-enhanced organogels and mesomorphic superstructure based on hydrazine derivatives.

Langmuir : the ACS journal of surfaces and colloids·2010
Same author

Cancer-derived mutations in the fibronectin III repeats of PTPRT/PTPrho inhibit cell-cell aggregation.

Cell communication & adhesion·2010
Same author

Simulation of wavelength conversion based on integrated saturable absorber.

Applied optics·2010
Same author

Traditional Chinese medicine in the treatment of rheumatoid arthritis: a general review.

Rheumatology international·2010

Related Experiment Video

Updated: Apr 1, 2026

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
03:50

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

3.3K

Acacetin Alleviates Loperamide-Induced Functional Constipation by Inhibiting P53-Mediated Apoptosis in Colonic

Xia Chen1, Ting Yang2, Yao Huang2

  • 1Department of Spleen and Stomach Disease, The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, China.

Neurogastroenterology and Motility
|March 30, 2026
PubMed
Summary

Acacetin, a compound in Yunweiling, treats functional constipation by inhibiting P53-mediated apoptosis in colon cells. This discovery offers new therapeutic insights for traditional Chinese medicine in managing constipation.

Keywords:
P53Yunweilingacacetinapoptosisfunctional constipationloperamide

More Related Videos

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.8K
Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

1.2K

Related Experiment Videos

Last Updated: Apr 1, 2026

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
03:50

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

3.3K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.8K
Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

1.2K

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Traditional Chinese Medicine

Background:

  • Functional constipation (FC) is a common gastrointestinal disorder with limited treatment options.
  • Yunweiling (YWL), a traditional Chinese herbal medicine, is used for constipation, but its mechanisms are not fully understood.
  • Acacetin is a key bioactive compound in YWL.

Purpose of the Study:

  • To investigate the protective effects and mechanisms of acacetin in alleviating functional constipation.
  • To explore the role of acacetin and YWL in colon epithelial cell apoptosis and related signaling pathways.

Main Methods:

  • Molecular docking identified acacetin as a P53 target.
  • A loperamide-induced FC mouse model assessed acacetin's effects on motility, histology, and signaling.
  • Human colonic cells studied YWL and acacetin's protection against apoptosis and P53 pathway involvement.

Main Results:

  • Acacetin improved gastrointestinal motility and colon histology in FC mice.
  • Acacetin suppressed P53 upregulation and apoptosis in FC mice and colonic cells.
  • YWL and acacetin's protective effects were dependent on P53 inhibition.

Conclusions:

  • Acacetin alleviates functional constipation by inhibiting P53-mediated apoptosis in colonic epithelial cells.
  • This study elucidates the therapeutic mechanisms of YWL in constipation treatment.
  • Acacetin presents a potential therapeutic agent for functional constipation.